Ryvu Therapeutics

Ryvu Therapeutics Equity

The The Equity of Ryvu Therapeutics (RVU.WA) as of Oct 20, 2026 is 53.83 M PLN. In the previous year, The Equity was 143.88 M PLN — a change of -62.59% (lower).

Equity

53.83 MPLN

YoY

-62.59%

Last updated:

In 2025, Ryvu Therapeutics's equity was 53.83 M PLN, a -62.59% increase from the 143.88 M PLN equity in the previous year.

The Ryvu Therapeutics Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
191.91 M PLN
Jan 1, 2019
119.76 M PLN
Jan 1, 2020
223.72 M PLN
Jan 1, 2021
161.30 M PLN
Jan 1, 2022
343.39 M PLN
Jan 1, 2023
259.59 M PLN
Jan 1, 2024
143.88 M PLN
Jan 1, 2025
53.83 M PLN
The Ryvu Therapeutics Equity history
YEAREquityYoY
53.83 MPLN-62.59%
143.88 MPLN-44.57%
259.59 MPLN-24.40%
343.39 MPLN+112.89%
161.30 MPLN-27.90%
223.72 MPLN+86.81%
119.76 MPLN-37.60%
191.91 MPLN+208.06%
62.30 MPLN+12.50%
55.37 MPLN+19.22%
46.45 MPLN+401.95%
9.25 MPLN—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Ryvu Therapeutics Stock analysis

What does Ryvu Therapeutics do? Ryvu Therapeutics SA is a Polish biotechnology company specializing in the research and development of innovative therapies for various types of cancers. The company was founded in 2015 and is headquartered in Krakow. Ryvu Therapeutics SA has gained a good reputation since its establishment and has attracted numerous renowned investors and partners. The company's business model focuses on the research and development of drugs based on new molecular therapies that can inhibit the activity of specific proteins in cancer patients. The company's strategy is to develop a wide range of innovative therapies with different mechanisms of action to maximize the potential of helping cancer patients. Ryvu Therapeutics SA operates in three main areas: research and development, preclinical development, and clinical development. The company has a highly experienced team of scientists and researchers dedicated to developing new anti-cancer drugs. The research focus is on identifying new therapeutic targets and molecules or compounds that can inhibit the activity of these targets. After identifying promising molecules in the research phase, the company conducts extensive preclinical studies to assess the safety and efficacy of the drug candidates. Different models are used to test the effects of the new therapies in vitro and in vivo. Upon successful completion of the preclinical phase, the company moves on to clinical development, where the effectiveness and safety of the drugs are evaluated in clinical trials in humans. Phase I clinical trials are conducted to determine the tolerability and dosage of the drug candidates. Phase II and III trials investigate the efficacy and safety of the drug in a larger number of patients. Ryvu Therapeutics SA has several molecules and compounds in its portfolio that are currently in different stages of development. Some examples include SEL120, a potential new drug that inhibits the activity of the CDK8 protein, which plays a crucial role in the development of cancer. SEL120 is currently in Phase I clinical trials. SEL201 is another drug candidate that targets CDK8 and is still in the preclinical research phase. SEL110 is a small molecule that targets the BCL-XL protein and has the potential to be effective against multiple types of cancer. It is currently in the early phase of clinical development. In conclusion, Ryvu Therapeutics SA is an innovative biotech company specializing in the development of new cancer therapies. The company already has several promising drug candidates in its portfolio, targeting different therapeutic targets and currently in various stages of development. Ryvu Therapeutics SA shows great potential to play a significant role in the treatment of cancer. Ryvu Therapeutics is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Ryvu Therapeutics's Equity

Ryvu Therapeutics's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Ryvu Therapeutics's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Ryvu Therapeutics's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Ryvu Therapeutics's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Ryvu Therapeutics’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Ryvu Therapeutics stock

The Equity of Ryvu Therapeutics is 53.83 M PLN in 2025.

The Equity of Ryvu Therapeutics changed from 143.88 M PLN to 53.83 M PLN, representing a -62.59% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Ryvu Therapeutics since 2006 – with annual values, charts, and detailed analysis.

The Equity's PLN is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Ryvu Therapeutics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Ryvu Therapeutics

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Ryvu Therapeutics